Organisation paid for research Program year 2025 Source: CMS Open Payments

Cardiovascular Associates Research

Neither a doctor nor a teaching hospital

Research payments

$983,867

106 payments

Through program year 2025, Cardiovascular Associates Research is reported as receiving $983,867 in research payments, across 106 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $179,414 6
2024 Research $336,646 8
2023 Research $200,848 5
2022 Research $191,074 27
2021 Research $3,800 8
2020 Research $16,115 23
2019 Research $55,970 29

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $874,447 14 payments
  2. CSL Behring $108,420 91 payments
  3. Boston Scientific Corporation $1,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $342,388 3 payments
  2. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $265,163 4 payments
  3. A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $97,479 1 payment
  4. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $93,506 3 payments
  5. A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $60,911 1 payment
  6. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $55,970 29 payments
  7. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $52,450 62 payments
  8. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C $8,000 1 payment
  9. A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD $7,000 1 payment
  10. LSS of 4 Site $1,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record